STAGE IIIB BLADDER CANCER AJCC V8
Clinical trials for STAGE IIIB BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIB BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IIIB BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Personalized cancer fight: matching drugs to your Tumor's genetic fingerprint
Disease control OngoingThis study is testing whether specific genetic markers in a patient's tumor can predict if they will respond well to immunotherapy drugs. It is for people with advanced bladder cancer that has spread and has stopped responding to standard chemotherapy. Participants receive two im…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
New drug duo targets tough bladder cancers
Disease control OngoingThis early-stage trial is testing a combination of two targeted drugs, erdafitinib and enfortumab vedotin, for people with advanced bladder cancer that has spread and has specific genetic changes (FGFR2/3). The main goals are to find the safest and most effective dose of the drug…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New cancer combo aims to supercharge immune system while taming side effects
Disease control OngoingThis study is testing a combination of three immunotherapy drugs—tocilizumab, ipilimumab, and nivolumab—in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. The main goal is to see if adding tocilizumab can help manage the serious side effects someti…
Matched conditions: STAGE IIIB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC